‹ Browse★ Saved
📱 Tech & Apps
Beam Therapeutics
(BEAM ↗)
beamtx.com ↗
Beam is the leading public *base-editing* biotech — a precision form of gene editing that rewrites a single DNA letter without cutting the strand. The company has $1.2 billion of cash and zero approved drugs. The race is to land the first base-editing therapy in the FDA's hands before the bank runs low.
Updated · Q1 2026 · May 2026
6
Chapters
~16
Min read
~$165M / yr (collaboration) revenue · ~510 employees · public since 2020
🌶️🌶️🌶️🌶️
Spice: Ghost (5/5)
More filled = spicier (more aggressive), not "better." Tap a row to see what it means.
What is spice?
Your progress
0 of 6
1
Growth
~3 min
Revenue Isn't the Number Yet
Beam's revenue is *up 4x* year over year — but it's not from selling drugs.
›
2
Financial Health
~3 min
$1.2B and a 2029 Clock
Beam has *more than three years* of runway. For a biotech, that's the cushion that buys clinical trials.
›
3
Moat
~3 min
Base Editing, Patented Tools
Beam isn't trying to be a one-drug story. It's trying to own a *platform* — and the patents to defend it.
›
4
Management
~2 min
Founder Science, Operator CEO
Beam pairs an academic-celebrity founder with a CEO whose job is to translate the science into a drug.
›
5
Behind the Numbers
~2 min
The Story Behind the Numbers
The numbers in a biotech earnings release are *signposts.* The story is in the milestones.
›
6
Risk
~3 min
The Binary Bets
Beam isn't a runway risk — it's a *trial-readout* risk. Every share is a bet on the next data drop.
↻ Next update · Aug 5
est. Aug 5, 2026 · Q2 2026 · Beam Therapeutics IR ↗
›
✦ Reader takes on Beam Therapeutics
0 comments
Drop your read. See how others are calling this brief.
No one's weighed in yet. Be the first.
↗ Share Beam Therapeutics
↻ The read keeps updating
You're reading the 6 opening chapters. After that, every time Beam files a new report, the chapters get updated here.